ADVFN US – Market Content Editor
-
Oil prices steady as attention turns to U.S.-Russia talks and China trade truce extension
Oil markets showed little movement during Tuesday’s Asian trading session as investors focused on upcoming talks between the U.S. and Russia, which could potentially bring an end to the war in Ukraine and offer relief to major oil consumers like India and China. Prices received some support after the U.S. and China agreed to extend…
-
UBS lifts lithium price outlook as CATL halts Chinese mining operations
UBS has revised its lithium price projections upward following the suspension of mining activities by CATL at its Jianxiawo lepidolite site in China, intensifying supply concerns amid heightened regulatory oversight. Operations were halted after CATL’s mining license expired on August 9, with the company indicating the shutdown would last “at least 3 months,” according to…
-
Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial
Novartis (NYSE:NVS) announced that its investigational antibody, ianalumab, combined with eltrombopag, successfully met the primary endpoint in a Phase 3 study (VAYHIT2) involving patients with primary immune thrombocytopenia (ITP). The therapy notably prolonged the time until treatment failure, assessing how long patients maintained safe platelet counts during and after treatment. Following the news, Novartis shares…
-
Ford Issues Recall for Over 103,000 Vehicles Over Axle Hub Spline Defect
Ford Motor Company (NYSE:F) is recalling 103,174 vehicles across the U.S. due to a potential safety defect involving damaged axle hub splines, the National Highway Traffic Safety Administration (NHTSA) reported. The recall stems from concerns that affected vehicles might roll away if placed in park without the parking brake engaged. Additionally, the damaged axle hub…
-
AST SpaceMobile Shares Surge 13% Premarket Following Satellite Launch Update
AST SpaceMobile (NASDAQ:ASTS) saw its shares climb by 13% in early U.S. trading on Tuesday after the company announced a revised schedule for launching its next set of BlueBird satellites. The firm, which specializes in satellite-to-smartphone connectivity, aims to build a high-speed cellular broadband network by deploying its constellation of low-Earth-orbit BlueBird satellites. Notable investors…
-
U.S. Stocks Finish Choppy Trading Day Moderately Lower
Following the strong upward move seen in the previous week, stocks showed a lack of direction over the course of the trading session on Monday. The major averages spent the day bouncing back and forth across the unchanged line. The major averages eventually ended the day in negative territory. While the slid 200.52 points or…
-
Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection
Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron Sucrose Injection, USP, marking the first generic alternative to Venofer® Injection. This intravenous iron replacement therapy is prescribed for iron deficiency anemia in both adult and pediatric patients suffering from chronic kidney disease. The product will…
-
VivoPower Shares Jump After Announcement to Acquire Ripple Labs Equity
VivoPower International PLC (NASDAQ:VVPR) saw its stock climb 9% following news of its intent to acquire shares in Ripple Labs, enhancing its strategy centered around XRP digital assets in its treasury. The company has allocated an initial $100 million to buy privately held Ripple shares after completing a two-month due diligence process. These purchases remain…
-
Amphastar Shares Rise Following FDA Approval of Generic Iron Sucrose Injection
Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock increase by 4% after the company announced that the FDA had approved its generic version of iron sucrose injection, a treatment used for iron deficiency anemia in patients with chronic kidney disease. The newly authorized medication, formerly known as AMP-002, will be offered in three dosage strengths: 50mg/2.5mL, 100mg/5mL,…
-
IO Biotech Shares Climb Following Encouraging Cancer Vaccine Trial Results
IO Biotech (NASDAQ:IOBT) stock gained 6.1% after revealing topline data from its pivotal Phase 3 trial evaluating Cylembio, an experimental cancer vaccine, combined with Merck’s (NSE:PROR) KEYTRUDA in patients with advanced melanoma. The study demonstrated clinical benefits in progression-free survival (PFS) for the combination treatment versus KEYTRUDA alone, though it narrowly fell short of statistical…